Results 181 to 190 of about 25,638 (254)
Effects of Liraglutide on Energy Intake in Adolescents With Persistent Obesity After Vertical Sleeve Gastrectomy. [PDF]
Tran BC +14 more
europepmc +1 more source
Bibliometric analysis of 3736 publications (2004–2025) reveals rapid growth in GLP‐1–based T2DM research. The US leads, with Novo Nordisk and Eli Lilly as top contributors. Thematic shifts from glycemic control toward cardiovascular‐kidney‐metabolic outcomes and real‐world evidence, driven by landmark trials like LEADER and REWIND.
Yanbing Wang +6 more
wiley +1 more source
Reporting patterns of suicide- and self-injury-related events involving liraglutide, semaglutide, and tirzepatide: data from the European pharmacovigilance database. [PDF]
Scavone C +6 more
europepmc +1 more source
A clinical and experimental investigation of liraglutide effects on the brain-kidney axis. [PDF]
Greenwood MP +6 more
europepmc +1 more source
ABSTRACT Aims Tirzepatide is a once‐weekly glucose‐dependent insulinotropic polypeptide and glucagon‐like peptide‐1 receptor agonist (GLP‐1 RA) approved in the US for the treatment of Type 2 diabetes (T2D), weight loss and obstructive sleep apnoea. This study aimed to assess the utilisation and effectiveness of tirzepatide among individuals in a large ...
Theresa Hunter Gibble +7 more
wiley +1 more source
Economic evaluation of liraglutide versus sitagliptin in the treatment of type 2 diabetes mellitus inadequately controlled with metformin. [PDF]
Yang F, Zheng X, Li W, Zhao Z.
europepmc +1 more source
ABSTRACT Aims The association between glucagon‐like peptide‐1 receptor agonist (GLP‐1RA) use and the development of bowel obstruction/ileus remains unclear, and evidence for specific bowel obstruction/ileus subtypes remains limited. We examined the association between GLP‐1RA use and the incidence of bowel obstruction/ileus subtypes across different ...
Yuichiro Matsuo +3 more
wiley +1 more source
GLP-1 Receptor Agonists and Tirzepatide in Men Seeking Fertility: A Structured Narrative Review and Proposed Clinical Framework. [PDF]
Kaltsas A +6 more
europepmc +1 more source
ABSTRACT Background Body composition changes during glucagon‐like peptide‐1 (GLP‐1)‐based therapy remain incompletely characterized, particularly regarding their effects on adiposity, muscle quantity, and muscle quality. We conducted a systematic review and meta‐analysis using a predefined physiological framework to evaluate body composition ...
Maria Luizza Lopes Menezes +6 more
wiley +1 more source

